{"filings":[{"id":917918,"accession_number":"0001193125-26-261658","cik":1382101,"company_name":"SUTRO BIOPHARMA, INC.","ticker":"STRO","form_type":"8-K","filed_at":"2026-06-08T20:01:05+00:00","items":["5.07"],"status":"ready","headline":"Sutro Biopharma stockholders elect three Class II directors and ratify auditor at 2026 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Directors Jane Chung (11.4M for), Connie Matsui (9.7M for), James Panek (9.7M for) elected to three-year terms.","Ratification of Ernst & Young as auditor for 2026 passed with 13.9M for, 501 against.","Non-binding advisory vote on named executive officer compensation approved with 11.3M for.","Broker non-votes totaled 2,540,863 on director election and say-on-pay items."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":495414747.42160654,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":442921,"accession_number":"0001193125-26-224065","cik":1382101,"company_name":"SUTRO BIOPHARMA, INC.","ticker":"STRO","form_type":"8-K","filed_at":"2026-05-14T20:15:18+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sutro Q1 cash $202.6M; revenue $14.5M; luvelta closed; STRO-004 data mid-2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $202.6M as of Mar 31, 2026 (vs $141.4M Dec 2025); $110M stock offering extends runway into Q2 2028.","Q1 revenue $14.5M (down from $17.4M YoY); total R&D+G&A $44.1M (down from $64.9M YoY).","STRO-004 Phase 1 dose-escalation ongoing; initial safety, PK, activity data expected mid-2026.","Astellas collaboration: first TROP2 dual-payload iADC in clinic; $10M milestone received April 2026.","Luvelta program closed; no further investment or business development efforts."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.94,"consensus_revenue_estimate":null,"consensus_revenue_actual":14523000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":495414747.42160654,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103429,"accession_number":"0001193125-26-119844","cik":1382101,"company_name":"SUTRO BIOPHARMA, INC.","ticker":"STRO","form_type":"8-K","filed_at":"2026-03-23T23:59:59+00:00","items":["1.02","2.02","9.01"],"status":"ready","headline":"Sutro Biopharma reports FY2025 revenue $102.5M; cash runway extended into Q2 2028","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Cash $141.4M at Dec 31, 2025; $110M underwritten offering extends runway into Q2 2028.","Revenue $102.5M (FY2025) vs $62.0M in 2024; R&D+G&A expenses reduced to $207.4M from $300.5M.","Terminated ATM Sales Agreement with Jefferies effective March 23, 2026.","STRO-004 Phase 1 dosed three cohorts; initial data mid-2026. STRO-227 IND submission on track for 2026.","Astellas TROP2 iADC program entered clinic; $10M milestone expected Q2 2026. Second program triggers $7.5M milestone."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":495414747.42160654,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103428,"accession_number":"0001193125-26-044934","cik":1382101,"company_name":"SUTRO BIOPHARMA, INC.","ticker":"STRO","form_type":"8-K","filed_at":"2026-02-10T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Sutro Biopharma raises $110M in underwritten public offering of 7.87M shares at $13.98/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 7,868,383 shares at $13.98 per share; gross proceeds approximately $110.0 million.","Underwriters include Leerink Partners and TD Securities; closing expected February 11, 2026.","Proceeds to fund research, clinical development, manufacturing, and general corporate purposes.","Combined with existing cash, total capital resources estimated at $251.4 million; cash runway into Q2 2028.","Offering made under existing shelf registration statement; customary underwriting agreement terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":495414747.42160654,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119673,"accession_number":"0001193125-25-322859","cik":1382101,"company_name":"SUTRO BIOPHARMA, INC.","ticker":"STRO","form_type":"8-K","filed_at":"2025-12-17T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Sutro Biopharma regains Nasdaq minimum bid price compliance after prior deficiency","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received Nasdaq notice on Dec 17, 2025 confirming compliance with Listing Rule 5450(a)(1) after 10 consecutive business days with closing bid at or above $1.00.","Non-compliance was initially disclosed on June 20, 2025 when bid price fell below $1.00 for 30 consecutive business days.","Listing matter is now closed; company meets all other Nasdaq Global Market continued listing criteria."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":495414747.42160654,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119672,"accession_number":"0001193125-25-306786","cik":1382101,"company_name":"SUTRO BIOPHARMA, INC.","ticker":"STRO","form_type":"8-K","filed_at":"2025-12-03T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"Sutro Biopharma announces 1-for-10 reverse stock split effective Dec 3 to regain Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1-for-10, effective 12:01 a.m. ET on December 3, 2025.","Outstanding shares reduced from ~85.2M to ~8.52M; symbol STRO unchanged, new CUSIP 869367201.","Intended to regain Nasdaq minimum bid price compliance; approved by stockholders on June 6, 2025.","No fractional shares issued; any fractional interest rounded up to nearest whole share.","Proportionate adjustments to equity awards, exercise prices, and shares reserved under equity plans."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":495414747.42160654,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119671,"accession_number":"0001193125-25-269833","cik":1382101,"company_name":"SUTRO BIOPHARMA, INC.","ticker":"STRO","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sutro Biopharma Q3 revenue $9.7M, cash $167.6M; IND cleared for STRO-004","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FDA cleared IND for STRO-004 (Tissue Factor ADC); first patient dosing expected before year-end.","Cash, cash equivalents and marketable securities were $167.6M at Sept. 30, 2025, down from $388.3M a year earlier.","Revenue was $9.7M (vs $8.5M Q3 2024), primarily from Astellas collaboration.","R&D and G&A expenses totaled $48.6M, down from $76.4M in Q3 2024.","Organizational restructuring expected to extend cash runway into at least mid-2027; restructuring costs estimated at $4.1M–$4.3M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":90837000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":495414747.42160654,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136245,"accession_number":"0001193125-25-223434","cik":1382101,"company_name":"SUTRO BIOPHARMA, INC.","ticker":"STRO","form_type":"8-K","filed_at":"2025-09-29T23:59:59+00:00","items":["2.05","9.01"],"status":"ready","headline":"Sutro Biopharma cuts workforce ~33%; extends cash runway to mid-2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Workforce reduction of approximately one-third to prioritize three preclinical ADC programs.","Expected cash runway extended into at least mid-2027 due to restructuring and milestone payments.","Initial clinical data from STRO-004 (Tissue Factor-targeting exatecan ADC) expected in 2026.","Restructuring costs estimated at $4.1-4.3 million, with majority paid in Q4 2025.","Company plans to initiate clinical studies for at least one additional ADC program beyond STRO-004."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":495414747.42160654,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136244,"accession_number":"0000950170-25-105159","cik":1382101,"company_name":"SUTRO BIOPHARMA, INC.","ticker":"STRO","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sutro Q2 revenue $63.7M; cash $205.1M; STRO-004 IND on track for H2 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $63.7M, up 148% YoY, driven by Astellas collaboration and Ipsen deferred revenue recognition.","Cash, equivalents and marketable securities $205.1M; cash runway into early 2027.","R&D and G&A expenses $48.7M (down 35% YoY); restructuring costs $18.4M from luvelta deprioritization.","STRO-004 FIH trial on track for H2 2025; STRO-006 clinical in 2026; dual-payload ADC IND filing in 2027.","Astellas milestone triggered $7.5M payment; Ipsen terminates STRO-003; Greg Chow appointed CFO."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":81144000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":495414747.42160654,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153321,"accession_number":"0000950170-25-089978","cik":1382101,"company_name":"SUTRO BIOPHARMA, INC.","ticker":"STRO","form_type":"8-K","filed_at":"2025-06-25T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Sutro Biopharma receives Nasdaq minimum bid price deficiency notice; has until Dec 17, 2025 to cure","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq notified Sutro on June 20, 2025 of non-compliance with $1.00 minimum bid price rule.","Company has 180 calendar days, until December 17, 2025, to regain compliance by closing at $1.00 for 10 consecutive days.","If not cured, Sutro may transfer to Nasdaq Capital Market for a second 180-day period or face delisting.","Sutro plans to monitor bid price and may implement a reverse stock split if needed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":495414747.42160654,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153320,"accession_number":"0001193125-25-138481","cik":1382101,"company_name":"SUTRO BIOPHARMA, INC.","ticker":"STRO","form_type":"8-K","filed_at":"2025-06-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Sutro Biopharma stockholders approve reverse stock split at 1:5 to 1:25 ratio","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split authorized at ratio between 1:5 and 1:25, board to set exact ratio.","Three Class I directors elected: Heidi Hunter, Jon Wigginton, Michael Dybbs for three-year terms.","Ernst & Young LLP ratified as independent auditor for fiscal year ending Dec 2025 with 99.1% for.","Non-binding advisory vote on named executive officer compensation passed with 42.99M for.","All proposals passed at June 6, 2025 annual meeting; broker non-votes ranged from 12.5M on director elections."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":495414747.42160654,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153319,"accession_number":"0001193125-25-133268","cik":1382101,"company_name":"SUTRO BIOPHARMA, INC.","ticker":"STRO","form_type":"8-K","filed_at":"2025-06-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Sutro Biopharma appoints Gregory K. Chow as CFO effective June 2, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Gregory K. Chow appointed CFO, principal financial and accounting officer, effective June 2, 2025.","Base salary $475,000; target annual bonus 40% of base salary.","Receives option for 275,000 shares (4-year vest) and 100,000 RSUs (4-year vest).","Prior roles: CFO of NodThera (Aug 2024-Mar 2025), Freenome (Jan-Aug 2024), Frontier Medicines (Mar 2021-Dec 2024).","Severance on non-cause termination: 15 months salary + pro-rata bonus + COBRA; full acceleration upon change in control within 18 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":495414747.42160654,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153318,"accession_number":"0000950170-25-067061","cik":1382101,"company_name":"SUTRO BIOPHARMA, INC.","ticker":"STRO","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sutro Q1 revenue $17.4M, cash $249M; restructures to focus on next-gen ADCs, headcount cut ~50%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $17.4M vs $13.0M Q1 2024; cash $249M down from $316.9M Dec 2024; runway into early 2027.","Restructuring: headcount reduced ~50%, manufacturing facility decommissioned by year-end 2025; luvelta deprioritized.","Lead candidate STRO-004 (Tissue Factor ADC) IND expected 2H 2025; STRO-006 IND 2026; dual-payload ADC IND 2027.","Astellas collaboration triggers $7.5M milestone from IND-enabling tox study for iADC program.","Restructuring cost $21M in Q1; expects further significant costs in 2025 for wind-down of luvelta trials."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.91,"consensus_revenue_estimate":null,"consensus_revenue_actual":17399000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":495414747.42160654,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153317,"accession_number":"0000950170-25-053733","cik":1382101,"company_name":"SUTRO BIOPHARMA, INC.","ticker":"STRO","form_type":"8-K","filed_at":"2025-04-14T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director John Freund not standing for re-election at June 6, 2025 Annual Meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John Freund, board member since 2014, will not stand for re-election at the Annual Meeting on June 6, 2025.","His term expires following the meeting; no disagreement with company operations, policies, or practices.","Freund will continue to advise management as a consultant after his board term ends."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":495414747.42160654,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172109,"accession_number":"0000950170-25-038879","cik":1382101,"company_name":"SUTRO BIOPHARMA, INC.","ticker":"STRO","form_type":"8-K","filed_at":"2025-03-13T23:59:59+00:00","items":["2.02","2.05","5.02","9.01"],"status":"ready","headline":"Sutro restructures with 50% layoffs, deprioritizes luvelta; CEO Newell steps down, Jane Chung appointed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Jane Chung appointed CEO, replaces Bill Newell effective March 13, 2025; CFO and CMO also transitioning.","Workforce reduced ~50%; luvelta (STRO-002) development halted; out-licensing sought.","Cash, cash equivalents & marketable securities $316.9M as of Dec 31, 2024; cash runway into at least Q4 2026.","Restructuring costs estimated $40-$45 million, largely in 2025; revenue $62M in FY2024 vs $153.7M in 2023.","Three IND filings planned over next 3 years: STRO-004 (Tissue Factor ADC) expected 2H 2025, STRO-006 in 2026, dual-payload ADC in 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":495414747.42160654,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189082,"accession_number":"0000950170-24-134765","cik":1382101,"company_name":"SUTRO BIOPHARMA, INC.","ticker":"STRO","form_type":"8-K","filed_at":"2024-12-10T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Sutro selects luvelta dose for registrational ovarian cancer trial; 32% ORR in Part 1","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Selected dose: 5.2 mg/kg with prophylactic pegfilgrastim for 2 cycles then 4.3 mg/kg for subsequent cycles.","Topline Part 1 (5.2 mg/kg, N=25): ORR 32%, DCR 96%; half of patients ineligible for approved FRα-targeting ADC.","88% of patients received prior bevacizumab; Grade 3+ neutropenia 32%, no febrile neutropenia.","Part 2 registrational trial to enroll ~500 patients randomized 1:1 luvelta vs investigator's choice chemo."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":495414747.42160654,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189081,"accession_number":"0000950170-24-126382","cik":1382101,"company_name":"SUTRO BIOPHARMA, INC.","ticker":"STRO","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sutro Biopharma Q3 2024: revenue $8.5M, cash $388.3M, luvelta registrational trial underway","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Cash, equivalents, and marketable securities $388.3M as of September 30, 2024.","Revenue $8.5M for Q3 2024, down from $16.9M in Q3 2023 (49.7% decrease).","Total operating expenses $76.4M, up from $60.9M in Q3 2023; R&D $62.1M, G&A $14.3M.","Realized gain of $32.1M from sale of Vaxcyte shares; no remaining Vaxcyte holdings.","Initiated registrational trial for luvelta in pediatric leukemia; IND for STRO-004 expected H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":47234000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":495414747.42160654,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205566,"accession_number":"0000950170-24-096313","cik":1382101,"company_name":"SUTRO BIOPHARMA, INC.","ticker":"STRO","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sutro reports Q2 revenue $25.7M, cash $426M; luvelta trials advancing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $25.7M (up from $10.4M YoY) driven by Astellas collaboration and Vaxcyte agreement.","Cash, equivalents, and securities $375.6M; Vaxcyte stock fair value $50.4M (total $426M).","Operating expenses $74.4M (R&D $62.0M, G&A $12.4M); includes non-cash stock comp and depreciation.","Luvelta Phase 3 REFRαME-O1 randomized portion underway; pediatric AML trial (REFRαME-P1) expected H2 2024.","Appointed Sukhi Jagpal to Board and Barbara Leyman as Chief Business Development Officer."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":38714000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":495414747.42160654,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205565,"accession_number":"0000950170-24-095486","cik":1382101,"company_name":"SUTRO BIOPHARMA, INC.","ticker":"STRO","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Sutro Biopharma appoints Sukhi Jagpal to Board of Directors and Audit Committee","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Sukhi Jagpal appointed as Class III director effective August 8, 2024, and to Audit Committee effective August 15, 2024.","Jagpal receives pro rata portions of $40,000 director retainer and $10,000 Audit Committee retainer for remainder of year.","Granted stock options: 35,000 shares (3-year monthly vest) and 28,959 shares (vesting until 2025 annual meeting).","Standard indemnification agreement entered; no family relationships or material transactions with existing officers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":495414747.42160654,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222506,"accession_number":"0000950170-24-071335","cik":1382101,"company_name":"SUTRO BIOPHARMA, INC.","ticker":"STRO","form_type":"8-K","filed_at":"2024-06-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Sutro Biopharma stockholders elect Lobacki, Petree; ratify EY; approve say-on-pay & ESPP amendment","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Joseph M. Lobacki re-elected with 49.6M shares For (1.4M Withheld); Daniel H. Petree re-elected with 33.4M For (17.6M Withheld).","Ernst & Young ratified as independent auditor for FY 2024: 64.6M For, 118.9K Against, 161.9K Abstain.","Non-binding advisory approval of named executive officer compensation: 50.2M For, 171.2K Against, 587.3K Abstain.","Amendment to 2018 Employee Stock Purchase Plan approved: 50.2M For, 618.7K Against, 129.4K Abstain (increase share limit + clarifying revisions)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":495414747.42160654,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222505,"accession_number":"0000950170-24-058701","cik":1382101,"company_name":"SUTRO BIOPHARMA, INC.","ticker":"STRO","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sutro Biopharma Q1 2024: Revenue $13.0M, Cash $267.6M; IND cleared for NSCLC trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2024 revenue of $13.0M (vs $12.7M YoY); total operating expenses $69.6M ($56.9M R&D, $12.7M G&A).","Cash and investments $267.6M plus $45.6M in Vaxcyte shares; April added $75M from Ipsen licensing and $75M equity offering.","IND cleared for luvelta in NSCLC; Phase 2 expected to start H2 2024, initial data H1 2025.","REFRαME-O1 registration trial for PROC now enrolling; pediatric AML trial expected to begin H2 2024.","STRO-003 licensed to Ipsen; Sutro eligible for up to $899M in milestones plus tiered royalties."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":13008000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":495414747.42160654,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222504,"accession_number":"0000950170-24-040345","cik":1382101,"company_name":"SUTRO BIOPHARMA, INC.","ticker":"STRO","form_type":"8-K","filed_at":"2024-04-02T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Sutro Biopharma launches $75M common stock offering at $5.18/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["14,478,764 shares offered at $5.18/share; gross proceeds ~$75M.","Underwriting agreement with BofA Securities; closing expected April 4, 2024.","Net proceeds for general corporate purposes including R&D and working capital.","Offering is dilutive to existing shareholders; trading symbol STRO on Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":495414747.42160654,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222503,"accession_number":"0000950170-24-039736","cik":1382101,"company_name":"SUTRO BIOPHARMA, INC.","ticker":"STRO","form_type":"8-K","filed_at":"2024-04-02T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Sutro licenses STRO-003 ADC to Ipsen for up to $900M; $50M upfront plus equity","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Exclusive global license to Sutro's STRO-003 (ROR1-targeting ADC) to Ipsen; total potential $900M.","$50M upfront license fee plus $25M equity investment (4.8M shares at 17% premium to 20-day VWAP).","Up to $447M in development/regulatory milestones and up to $360M in sales milestones.","Tiered royalties from low double-digit to mid-teen percentages on net sales.","Ipsen responsible for IND submission and all subsequent clinical/commercial activities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":495414747.42160654,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242027,"accession_number":"0000950170-24-035948","cik":1382101,"company_name":"SUTRO BIOPHARMA, INC.","ticker":"STRO","form_type":"8-K","filed_at":"2024-03-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sutro Biopharma reports FY2023 revenue of $153.7M and $333.7M cash, runway into H2 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $153.7M in FY2023 vs $67.8M in FY2022, driven by Vaxcyte option exercise and collaborations.","Cash and investments $333.7M plus Vaxcyte stock valued at $41.9M, providing runway into H2 2025.","Total operating expenses $243.0M; R&D $180.4M, G&A $62.6M; includes stock-based comp $24.9M, D&A $6.8M.","Jane Chung promoted to President and COO; enrollment in REFRαME-O1 for PROC ongoing, Part 1 expected complete H1 2024.","Vaxcyte paid $50M for manufacturing rights option, with additional $25M due within six months and up to $60M milestones."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":495414747.42160654,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242026,"accession_number":"0001193125-24-030094","cik":1382101,"company_name":"SUTRO BIOPHARMA, INC.","ticker":"STRO","form_type":"8-K","filed_at":"2024-02-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Sutro Biopharma adds $100M to at-the-market equity program via new shelf registration","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed prospectus supplement to 2023 Form S-3 shelf, increasing shares available under existing Sales Agreement with Jefferies by $100M.","Total remaining capacity as of Feb 9, 2024: $29.3M from prior shelf plus $100M new supplement = $129.3M.","Previously sold $70.7M under the 2021 shelf registration since April 2021.","Shares sold through Jefferies LLC as sales agent at prevailing market prices.","Legal opinion on share validity filed as Exhibit 5.1 from Fenwick & West."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":495414747.42160654,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242025,"accession_number":"0000950170-24-002690","cik":1382101,"company_name":"SUTRO BIOPHARMA, INC.","ticker":"STRO","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Sutro Biopharma reports ~$333M cash, luvelta data in ovarian cancer, AML, NSCLC trials planned","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash, equivalents, marketable securities ~$333M as of Dec 31, 2023; 0.7M shares of Vaxcyte stock valued ~$42M, funding into 2H2025.","Updated luvelta data in ovarian cancer: improved clinical outcomes and tolerability vs historical chemo; prophylactic G-CSF reduced neutropenia/dose delays.","Luvelta + bevacizumab showed clinical activity regardless of FolRα expression; preclinical NSCLC data showed single-dose activity and benefit with PD-1 blockade.","REFRαME-O1 registration trial in platinum-resistant ovarian cancer enrolling, Part 1 completion expected 1H2024, ~140 sites by end of 2024.","REFRαME-P1 trial initiation in pediatric CBF/GLIS AML planned 1H2024; IND submission in NSCLC planned 1H2024; endometrial cancer development ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":495414747.42160654,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259421,"accession_number":"0000950170-23-066112","cik":1382101,"company_name":"SUTRO BIOPHARMA, INC.","ticker":"STRO","form_type":"8-K","filed_at":"2023-11-27T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Vaxcyte exercises option, pays Sutro $50M; manufacturing rights agreement effective","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Vaxcyte exercised option on Nov 21, 2023, paying $50M cash as first installment.","Vaxcyte must pay an additional $25M within six months of exercise date.","Up to $60M in additional regulatory milestone payments could be paid to Sutro.","Manufacturing Rights Agreement grants Vaxcyte exclusive, perpetual, royalty-free license to manufacture extract.","Sutro can terminate if Vaxcyte breaches confidentiality or fails to pay; Vaxcyte can terminate on 60 days notice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":495414747.42160654,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259420,"accession_number":"0000950170-23-065482","cik":1382101,"company_name":"SUTRO BIOPHARMA, INC.","ticker":"STRO","form_type":"8-K","filed_at":"2023-11-21T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Sutro Biopharma promotes Jane Chung to President and COO effective Dec 1, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jane Chung, previously Chief Commercial Officer, appointed President and COO, a newly created role.","New compensation includes $560k base salary, up to 50% bonus, 35k stock options, and 100k RSUs.","Chung previously served as President/GM of AstraZeneca Canada and VP of Immuno-Oncology at AstraZeneca.","Role focuses on operational excellence, strategic growth, and cross-functional alignment across R&D and portfolio."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":495414747.42160654,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259419,"accession_number":"0000950170-23-063021","cik":1382101,"company_name":"SUTRO BIOPHARMA, INC.","ticker":"STRO","form_type":"8-K","filed_at":"2023-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sutro Biopharma Q3 2023: Revenue $16.9M, cash runway into H1 2025; luvelta data and new CSO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and investments $321.1M plus Vaxcyte shares valued at $34.0M projecting runway into first half 2025.","Q3 2023 revenue $16.9M, down from $25.1M in Q3 2022; operating expenses $60.9M vs $46.4M.","Luvelta showed encouraging anti-tumor activity in FolRα-selected endometrial cancer at ESMO 2023; AML compassionate use data at ASH 2023.","Dr. Hans-Peter Gerber appointed Chief Scientific Officer in September 2023.","REFRaME-O1 Phase 2/3 trial for platinum-resistant ovarian cancer enrollment underway; global registration discussions with FDA/EMA."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":40010000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":495414747.42160654,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259418,"accession_number":"0000950170-23-051917","cik":1382101,"company_name":"SUTRO BIOPHARMA, INC.","ticker":"STRO","form_type":"8-K","filed_at":"2023-10-04T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Sutro Biopharma and Vaxcyte finalize agreement triggering $5M payment; license amended","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Vaxcyte agrees to pay Sutro $5.0M upon mutual agreement on Form Definitive Agreement, reached Sept 28, 2023.","Amendment No. 3 modifies royalty reduction provisions, IP ownership, prosecution, and financial reporting terms.","Vaxcyte gains rights to independently source cell-free extract from CMOs and option to internally manufacture extract.","Amendment effective immediately; negotiated under December 2022 letter agreement between the companies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":495414747.42160654,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276700,"accession_number":"0000950170-23-041404","cik":1382101,"company_name":"SUTRO BIOPHARMA, INC.","ticker":"STRO","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sutro Q2 2023: cash $358M, revenue $10.4M, initiates pivotal luvelta trial, Blackstone deal","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and marketable securities $358.3M; Vaxcyte shares valued at $33.3M; runway into H1 2025.","Revenue $10.4M (down from $28.1M YoY); total operating expenses $56.6M (up from $47.5M).","Initiated REFRaME Phase 2/3 pivotal study for luvelta in platinum-resistant ovarian cancer; enrollment underway.","Received $140M upfront from Blackstone royalty monetization; eligible for up to $250M milestone payments.","Luvelta endometrial cancer data to be presented at ESMO 2023; updated ovarian data expected H2 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":23086000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":495414747.42160654,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294495,"accession_number":"0000950170-23-029731","cik":1382101,"company_name":"SUTRO BIOPHARMA, INC.","ticker":"STRO","form_type":"8-K","filed_at":"2023-06-26T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Sutro Biopharma sells 4% royalty on Vaxcyte products to Blackstone for $140M upfront","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 4% royalty interest in Vaxcyte's future net sales (including VAX-24) to Blackstone Life Sciences.","Received $140M upfront payment on June 23, 2023 from Blackstone.","Eligible for up to $250M additional payments upon achieving return thresholds.","Retains rights to discover and develop vaccines for non-infectious diseases, including cancer.","Agreed to covenants on amending, assigning, and terminating the License Agreement with Vaxcyte."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":495414747.42160654,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294494,"accession_number":"0000950170-23-027975","cik":1382101,"company_name":"SUTRO BIOPHARMA, INC.","ticker":"STRO","form_type":"8-K","filed_at":"2023-06-14T23:59:59+00:00","items":["1.02","5.07"],"status":"ready","headline":"BMS terminates collaboration on CC-99712; Sutro regains full rights","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BMS notified Sutro on June 9, 2023 of termination of Amended Collaboration and License Agreement for CC-99712.","Termination effective October 7, 2023; decision attributed to BMS portfolio prioritization.","After termination, Sutro regains sole worldwide rights to the BCMA-targeting antibody-drug conjugate program.","No financial terms, termination payments, or immediate impact on cash runway disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":495414747.42160654,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294493,"accession_number":"0000950170-23-021973","cik":1382101,"company_name":"SUTRO BIOPHARMA, INC.","ticker":"STRO","form_type":"8-K","filed_at":"2023-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sutro Biopharma Q1 2023: Revenue $12.7M, cash $251.5M, runway into H2 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and investments $251.5M plus Vaxcyte shares valued at $25.0M; cash runway into second half of 2024.","Revenue of $12.7M for Q1 2023 up from $5.9M in Q1 2022, primarily from Astellas, Merck, BMS collaborations.","Total Q1 operating expenses $54.9M ($39.4M R&D, $15.5M G&A) vs $45.0M in Q1 2022.","Luvelta Phase 1 dose-expansion data to be oral presentation at ASCO 2023; REFRaME registration trial initiation in Q2 2023.","Leadership changes: Venkatesh Srinivasan promoted to CTOO; Trevor Hallam stepping down as President/CSO effective May 31, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":12674000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":495414747.42160654,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294492,"accession_number":"0000950170-23-015323","cik":1382101,"company_name":"SUTRO BIOPHARMA, INC.","ticker":"STRO","form_type":"8-K","filed_at":"2023-04-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Sutro Biopharma CSO Dr. Trevor Hallam resigns, effective May 31, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Trevor Hallam resigns as President of Research and Chief Scientific Officer effective May 31, 2023.","Resignation is not due to any disagreement with management or the board.","No successor has been announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":495414747.42160654,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294491,"accession_number":"0000950170-23-012879","cik":1382101,"company_name":"SUTRO BIOPHARMA, INC.","ticker":"STRO","form_type":"8-K","filed_at":"2023-04-14T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Sutro Biopharma director Shalini Sharp resigns; Heidi Hunter named Audit Committee Chair","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Shalini Sharp resigned as Class III director and Audit Committee Chair effective April 10, 2023.","Resignation not due to any disagreement with management or the Board.","Heidi Hunter, current Class I director and Audit Committee member, appointed as new Audit Committee Chair effective April 13, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":495414747.42160654,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315089,"accession_number":"0000950170-23-010978","cik":1382101,"company_name":"SUTRO BIOPHARMA, INC.","ticker":"STRO","form_type":"8-K","filed_at":"2023-03-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sutro Biopharma reports FY2022 revenue $67.8M, cash runway into H2 2024; plans luvelta Phase 2/3 in Q2 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and investments of $302.3M plus Vaxcyte stock valued at $32.0M provide cash runway into H2 2024.","Revenue for FY2022 was $67.8M, up from $61.9M in FY2021, driven by collaboration payments.","Total operating expenses were $196.7M, up from $160.4M, with R&D at $137.2M and G&A at $59.5M.","Plans to initiate Phase 2/3 registration-directed study of luvelta in platinum-resistant ovarian cancer in Q2 2023.","Dr. Anne Borgman appointed Chief Medical Officer in February 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":495414747.42160654,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315088,"accession_number":"0000950170-23-004373","cik":1382101,"company_name":"SUTRO BIOPHARMA, INC.","ticker":"STRO","form_type":"8-K","filed_at":"2023-02-24T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Sutro Biopharma amends bylaws to align with SEC universal proxy rules and DGCL changes","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Revised advance notice provisions requiring additional disclosures from proposing stockholders and nominees.","Added requirement that stockholders using universal proxy rules certify compliance and provide evidence at least 5 business days before meeting.","Updated adjournment procedures and list of stockholders to conform to recent DGCL amendments.","Added emergency bylaw provision for director and officer authority during emergencies.","Incorporated ministerial, clarifying, and conforming changes to align with DGCL and universal proxy rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":495414747.42160654,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315087,"accession_number":"0000950170-23-000528","cik":1382101,"company_name":"SUTRO BIOPHARMA, INC.","ticker":"STRO","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Sutro STRO-002 Phase 1 shows 43.8% ORR in FolRα-selected ovarian cancer; registrational study Q2 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["STRO-002 (luvelta) Phase 1 dose-expansion: 43.8% ORR, median DOR 5.4 mo, median PFS 6.6 mo at 5.2 mg/kg in FolRα-selected (TPS>25%) patients.","FolRα-selected population (~80% of advanced ovarian cancer) drove benefit; unselected patients had 11.1% ORR.","Prophylactic pegfilgrastim reduced Grade 3+ neutropenia 85% (66.7% to 10%) and dose delays 60.6% at cycle 2.","Phase 2/3 registration-directed study REFRaME to start Q2 2023; potential accelerated approval based on ORR endpoint."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":495414747.42160654,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":333428,"accession_number":"0000950170-22-026823","cik":1382101,"company_name":"SUTRO BIOPHARMA, INC.","ticker":"STRO","form_type":"8-K","filed_at":"2022-12-20T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Sutro grants Vaxcyte option to manufacture and source extract for vaccines; receives $22.5M upfront","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Upfront payment of $22.5M: $7.5M in Vaxcyte common stock, $15M in cash.","Option exercise triggers $75M cash payment in two installments; regulatory milestones up to $60M additional.","Option period of five years, with potential acceleration on Vaxcyte change of control.","Vaxcyte gains authorization to source cell-free extract from an independent CMO for its licensed products.","Economic terms of existing agreements between Sutro and Vaxcyte remain unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":495414747.42160654,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":333427,"accession_number":"0000950170-22-023274","cik":1382101,"company_name":"SUTRO BIOPHARMA, INC.","ticker":"STRO","form_type":"8-K","filed_at":"2022-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sutro BioPharma Q3 revenue $25.1M, cash $287.3M; STRO-002 data at ASH, Phase 2 design by year end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $25.1M (up from $8.5M YoY); total operating expenses $46.4M.","Cash, equivalents and marketable securities $287.3M as of Sep 30, 2022; projected runway into first half 2024.","STRO-002 oral presentation at ASH 2022 for pediatric AML; Phase 1 ovarian data and Phase 2 design expected by end 2022.","Vaxcyte positive Phase 1/2 data for VAX-24; Sutro to receive 4% royalties on worldwide net sales.","Astellas collaboration with $90M upfront received; Merck $10M milestone triggered."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":59140000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":495414747.42160654,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":333426,"accession_number":"0000950170-22-019872","cik":1382101,"company_name":"SUTRO BIOPHARMA, INC.","ticker":"STRO","form_type":"8-K","filed_at":"2022-10-24T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Sutro Biopharma CMO Arturo Molina resigns; effective Nov 4, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Arturo Molina notified Sutro on Oct 18, 2022 of his resignation as Chief Medical Officer.","Resignation effective November 4, 2022; no successor announced.","Company states resignation not due to any disagreement with management or board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":495414747.42160654,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":350937,"accession_number":"0000950170-22-015573","cik":1382101,"company_name":"SUTRO BIOPHARMA, INC.","ticker":"STRO","form_type":"8-K","filed_at":"2022-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sutro Biopharma Q2 revenue $28.1M; Astellas collaboration adds $90M cash, cash runway into H1 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $28.1M (flat YoY); operating expenses $47.5M vs $37.9M in Q2 2021.","Cash $191.6M at June 30; plus $90M Astellas upfront in July, providing runway into H1 2024.","Entered iADC collaboration with Astellas for up to 3 targets; $90M upfront, $422.5M milestones per candidate.","Merck triggered $10M milestone upon first patient dosed in Phase 1 of MK-1484 (IL-2 agonist).","FDA signaled accelerated approval pathway possible for STRO-002 in platinum-resistant ovarian cancer; data expected H2 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":33993000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":495414747.42160654,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":350936,"accession_number":"0000950170-22-013078","cik":1382101,"company_name":"SUTRO BIOPHARMA, INC.","ticker":"STRO","form_type":"8-K","filed_at":"2022-07-26T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Sutro Biopharma receives $10M milestone from Merck after first patient dosed in Phase 1 collaboration study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Merck pays Sutro $10.0 million milestone following first patient dosing in Phase 1 study of a collaboration candidate.","No other financial terms or guidance disclosed; collaboration continues.","Specific investigational candidate not named in the filing.","Milestone payment triggers positive cash inflow for Sutro's development programs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":495414747.42160654,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":368145,"accession_number":"0000950170-22-012215","cik":1382101,"company_name":"SUTRO BIOPHARMA, INC.","ticker":"STRO","form_type":"8-K","filed_at":"2022-06-28T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Sutro Biopharma enters $90M upfront license deal with Astellas for ADCs up to 3 targets","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Astellas pays $90M upfront; Sutro eligible for up to $422.5M in milestones plus tiered royalties (low double-digit to mid-teen %).","Sutro can elect US cost/profit sharing on any product candidate, replacing royalties in the US.","Deal covers up to 3 biological targets selected by Astellas; Sutro handles preclinical development.","Termination includes Astellas' convenience termination on 30 days' notice and mutual termination for material breach."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":495414747.42160654,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":368144,"accession_number":"0000950170-22-011712","cik":1382101,"company_name":"SUTRO BIOPHARMA, INC.","ticker":"STRO","form_type":"8-K","filed_at":"2022-06-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Sutro Biopharma to present updated corporate presentation at JMP conference","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Corporate presentation attached as Exhibit 99.1, available on company website.","Presentation covers company overview as of June 2022; no financial or pipeline data disclosed in filing.","No material changes to business, guidance, or clinical programs announced in the 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":495414747.42160654,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":368143,"accession_number":"0000950170-22-011282","cik":1382101,"company_name":"SUTRO BIOPHARMA, INC.","ticker":"STRO","form_type":"8-K","filed_at":"2022-06-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Sutro Biopharma stockholders elect four Class I directors, approve say-on-pay and auditor at 2022 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Four Class I directors elected: Michael Dybbs, John G. Freund, Heidi Hunter, Jon Wigginton, each to serve three-year terms.","Ratification of Ernst & Young as independent auditor for FY2022 approved with 43,752,354 votes for, 11,569 against.","Advisory vote on named executive officer compensation (say-on-pay) approved with 40,921,442 for, 759,278 against.","Stockholders selected one-year frequency for future advisory votes on executive compensation; board adopts annual frequency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":495414747.42160654,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":368142,"accession_number":"0000950170-22-008525","cik":1382101,"company_name":"SUTRO BIOPHARMA, INC.","ticker":"STRO","form_type":"8-K","filed_at":"2022-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sutro Biopharma Q1 2022 revenue $5.9M; cash $192.1M; STRO-002 data expected H2 2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $5.9M vs $14.7M YoY; operating expenses $45.0M vs $33.7M; net loss not stated directly.","Cash, cash equivalents and marketable securities $192.1M as of Mar 31, 2022; runway into H2 2023.","Phase 1 dose-expansion data for STRO-002 (ovarian cancer) expected H2 2022; regulatory meetings planned mid-2022.","First patient dosed in STRO-002 + bevacizumab combo trial; endometrial cohort enrolling.","Tasly amended STRO-002 license: $25M upfront, up to $350M in milestones; Tasly to fund Greater China development."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":5897000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":495414747.42160654,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":368141,"accession_number":"0000950170-22-005825","cik":1382101,"company_name":"SUTRO BIOPHARMA, INC.","ticker":"STRO","form_type":"8-K","filed_at":"2022-04-20T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Sutro Biopharma amends Tasly license for STRO-002; gets $25M initial, up to $350M in milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment to Tasly license for STRO-002 in Greater China (China, HK, Macau, Taiwan).","Initial payment revised to $25M; $15M escrow in Q2 2022 payable on regulatory milestones.","Additional potential milestone payments up to $350M for development, regulatory, commercialization.","Tasly retains exclusive rights to develop and commercialize STRO-002 in the region.","Amendment effective April 18, 2022; full terms to be filed in Q2 2022 10-Q."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":495414747.42160654,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":387471,"accession_number":"0000950170-22-002316","cik":1382101,"company_name":"SUTRO BIOPHARMA, INC.","ticker":"STRO","form_type":"8-K","filed_at":"2022-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Sutro FY2021 revenue $61.9M, operating expenses $160.4M; cash $229.5M; Tasly payment at risk","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and marketable securities $229.5M at Dec 31, 2021, down from $326.5M; runway into H2 2023.","Revenue $61.9M (up 45% from $42.7M) from Merck, BMS, EMD Serono collaborations.","Operating expenses $160.4M (up 41% from $113.8M); R&D $104.4M, G&A $56.0M.","STRO-002 Phase 1 dose-expansion enrollment completed Nov 2021; registrational study discussions expected mid-2022.","Tasly seeks to renegotiate STRO-002 Greater China terms; $40M initial payment uncertain; Sutro considering remedies."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":61880000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":495414747.42160654,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-02-28T23:59:59+00:00|387471"}